* To be consumed as directed by physician.
Lenva 4 Mg Capsules
Lenvatinib 4 mg
Lenva contain lenvatinib 4 mg. Lenvatinib is a selective, oral multikinase inhibitor that has shown antitumor, antiangiogenic, and immunomodulatory activity across multiple cancer types. Lenvatinib is used as first-line treatment in patients with unresectable Hepatocellular Carcinoma (HCC). Dosage: Recommended dosage is based on actual body weight - 12 mg for patients greater than or equal to 60 kg or, 8 mg for patients less than 60 kg. Take Lenva capsules orally once daily with or without food, until disease progression or until unacceptable toxicity.
First-line Treatment of Patients with Unresectable HCC
Product Enquiry
